Document Type : original article


1 pediatric Congenital Hematologic Disorders Research Center, Research Institute for Childern's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Childern's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Pediatric Endocrinologist, Mofid Children Hospital,Shahid Beheshti Universityof Medical Science,Iran,Tehran

4 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.



Background: Leukemia is one of the most common malignancies in childhood, accounting for about 40 per million children under the age of 15 years. Acute lymphoblastic leukemia accounts for about 75% of these cases of leukemia. Regarding the improvement in life expectancy and the prolonged life of patients with acute lymphoblastic leukemia, identifying the long-term complications and effects of treatment in patients is necessary.
Methods: The present applied study is a cohort study based on the case-control method. In order to achieve the purpose of the study, 50 patients who had improved acute lymphoblastic leukemia were selected as a case group; the selections were conducted in a sequential manner in Mofid Children Hospital. 50 other people who had no history of ALL disease were selected as the control group. All information gathering processes including patient history, physical examination, and necessary tests were done by a pediatric hematology oncology subspecialties fellow and trained personnel with full supervision of Pediatric hematologist - oncologist. Blood samples were taken at 10-cc of fasting blood. Blood samples after centrifugation and storage at 20 ° C were used to measure serum fasting blood glucose, triglyceride (Slovak based on serum lipid profile), and insulin levels. All demographic information, BMI, clinical symptoms, laboratory tests, and treatments were recorded in both forms. Data were finally entered into SPSS version 21 and analyzed using the GEE method.
Results: the incidence of obesity was significantly higher in patients with ALL as compared with the controls. The risk of obesity in ALL patients was found to be approximately 9 times higher than the controls. In this study 6 (12%) patients in cases and 4 (%8) patients in controls had metabolic syndrome. There was no statistically significant difference between the groups in the incidence of metabolic syndrome, insulin resistance, and visceral obesity.
Conclusion: It is suggested that after acute lymphoblastic leukemia treatment in children, in addition to regular follow up for disease recurrence, the patients should be monitored about metabolic syndrome or any of its components, especially weight gain, and obesity.


  1. Kadan-Lottick N. Cancer and Benign tumor. In: Kliegman RM, Behrman RE, Jenson HB SB, editor. Nelson textbook of pediatrics. Philadelphia: Elsevier; 2016. p. 2097–3000.
  2. Kourti M, Tragiannidis A, Makedou A, Papageorgiou T, Rousso I, Athanassiadou F. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol. 2005 Sep; 27(9):499–501.
  3. Pizzo Ph A PD. Principal & practice of pediatric oncology. 6th ed. USA: Lipincot; 2011. 538–590 p.
  4. Hudson MM, Ness KK, Gurney JG, Mulrooney DA, Chemaitilly W, Krull KR, Green DM, Armstrong GT, Nottage KA, Jones KE, Sklar CA, Srivastava DK, Robison LL. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013 Jun; 309(22):2371–81.
  5. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, Mertens AN. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009 May; 27(14):2328–38.
  6. Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, Sklar CA, Robison LL, Oeffinger KC. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014 Apr; 32(12):1218–27.
  7. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL, Yasui Y. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008 Oct; 100(19):1368–79.
  8. Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, Yasui Y, Robison LL, Oeffinger KC. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008 Oct; 26 (28):4639–45.
  9. Oeffinger KC, Mertens AC, Sklar CA, Yasui Y, Fears T, Stovall M, Vik TA, Inskip PD, Robison LL; Childhood Cancer Survivor Study. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003 Apr; 21(7):1359–65.
  10. Iughetti L, Bruzzi P, Predieri B, Paolucci P. Obesity in patients with acute lymphoblastic leukemia in childhood. Ital J Pediatr. 2012 Jan; 38:4.
  11. Oeffinger KC, Adams-Huet B, Victor RG, Church TS, Snell PG, Dunn AL, Eshelman-Kent DA, Ross R, Janiszewski PM, Turoff AJ, Brooks S, Vega GL. Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 2009 Aug; 27(22):3698–704.
  12. Faienza MF, Delvecchio M, Giordano P, Cavallo L, Grano M, Brunetti G, et al. Metabolic syndrome in childhood leukemia survivors: a meta-analysis. Endocrine. 2015 Jun; 49(2):353–60.
  13. Lanzkowsky P. Manual of pediatric hematology and oncology. 5th ed. Philadelphia: Elsevier; 2010. 518–20 p.
  14. Farhangi H, Badiee Z B-HA. Evaluation of clinical symptoms and laboratory testsin patients with acute leukemia in Dr Sheikh Hematology-Oncology children’s hospital. Sci J Iran Blood Transfus Organ. 2010; 9(3):27–32.
  15. Moradveisi B, Yazdanifard P, Fathollahpour A. Prevalence of clinical and paraclinical features of leukemia among children with acute lymphoblastic leukemia in Sanandaj Besat Hospital, 2008- 2013. Blood-Journal [Internet]. 2017 Dec 1; 14(4):281–8. Available from:
  16. Jafari-Adli S, Jouyandeh Z, Qorbani M, Soroush A, Larijani B, Hasani-Ranjbar S. Prevalence of obesity and overweight in adults and children in Iran; a systematic review. J Diabetes Metab Disord. 2014; 13(1):121.
  17. Zareifar S, Shorafa S, Haghpanah S, Karamizadeh Z, Adelian R. Association of Serum Leptin Level with

Obesity in Children with Acute Lymphoblastic Leukemia. Iran J Pediatr Hematol Oncol. 2015; 5(3):116–24.

  1. Trimis G, Moschovi M, Papassotiriou I. Early Indicators of Dysmetabolic Syndrome in Young Survivors of

Acute Lymphoblastic Leukemia in Childhood as a Target for Preventing Disease. 2007; 29(5):309–14.

  1. Chow EJ, Pihoker C, Hunt K, Wilkinson K, Friedman DL. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer. 2007 Nov; 110(10):2313–20.
  2. Oudin C, Simeoni M-C, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P, Curtillet C, Poirée M, Thuret I, Play B, Massot MC, Chastagner P, Chambost H, Auquier P, Michel G. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood. 2011 Apr; 117(17):4442–8.
  3. Barbosa-cortés L, López-alarcón M, Mejía-aranguré JM, Klünder-klünder M, Rodríguez-zepeda MC, Rivera-márquez H, Vega-Martínez Al, Martin-Trejo J, Shum-Luis J, Solis-Labastida K, López-Aguilar E, Matute-González G, Bernaldez-Rios R. Adipokines , insulin resistance , and adiposity as a predictors of metabolic syndrome in child survivors of lymphoma and acute lymphoblastic leukemia of a developing country. 2017; 1–13.
  4. Reisi N, Azhir A, Hashemipour M, Raeissi P, Amini A, Moafi A. The metabolic syndrome in survivors of childhood acute lymphoblastic leukemia in Isfahan, Iran. J Res Med Sci. 2009 Mar; 14(2):111–6.